Drugs / AD04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07107074 | Nov 2023 → Dec 2026 expected | early-onset autosomal dominant Alzheimer disease | ADvantage Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-08 | ADvantage Therapeutics | Regulatory MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease advantagetherapeutics.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-26 | ADvantage Therapeutics | ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic advantagetherapeutics.com ↗ |
| 2023-12-01 | ADvantage Therapeutics | ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease advantagetherapeutics.com ↗ |
| 2023-04-08 | ADvantage Therapeutics | MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease advantagetherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07107074 ↗ |
| Route | Subcutaneous | “6 single s.c. injections” NCT07107074 ↗ |